Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology | PR Newswire [Video]

, /PRNewswire/ — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

ADCs are a cutting-edge class of cancer treatments that combine the targeting ability of antibodies with the potent cancer-killing power of drugs. This allows for the precise delivery of therapeutic agents directly to cancer cells, minimizing damage to healthy tissue and enhancing treatment efficacy.

Peter van de Sande, Head of Synaffix, said: “Boehringer Ingelheim is a leader in oncology treatment development, and the selection of our ADC technologies to further bolster their pipeline portfolio is a strong recognition of the potential of these technologies to maximize the therapeutic index …